 |
市场调查报告书
商品编码
1550612
全球原发性硬化性胆管炎市场：依药物类别、给药途径、通路及地区Primary sclerosing cholangitis Market, By Drug Class (Ursodeoxycholic acid, Corticosteroids, Azathioprine, Mercaptopurine, Budesonide, Obeticholic acid, Monoclonal antibody, Others), By Route of Administration, By Distribution Channel, By Geography |
||||||
预计2024年全球原发性硬化性胆管炎市场规模将达1.612亿美元，2024年至2031年复合年增长率为7.8%，2031年将达2.731亿美元。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2023年 | 2024年市场规模 | 1.612 亿美元 |
| 实际资料 | 2019-2023 | 预测期 | 2024-2031 |
| 预测 2024-2031 年复合年增长率： | 7.80% | 2031 年金额预测 | 2.731 亿美元 |
原发性硬化性胆管炎（PSC）是一种慢性进行性胆汁淤积性肝病，其特征是肝内和肝外胆管多灶性狭窄和纤维化。 70% 至 80% 的病例存在发炎性肠道疾病（通常是溃疡性大肠炎）。儘管 PSC 的确切原因尚不清楚，但它被认为是一种自体免疫疾病，由遗传易感性和环境触发因素的复杂相互作用引起。 PSC 的全球盛行率估计为每 10 万人中 13 至 16 人。目前，PSC 尚无治疗方法，治疗重点是减轻症状和减缓疾病进展。全球原发性硬化性胆管炎市场的成长是由诊断率上升和医疗保健支出增加所推动的。
市场动态：
原发性硬化性胆管炎的全球市场成长是由人们对该疾病的认识不断提高、先进诊断方法提高诊断率以及全球易患 PSC 的老年人口增加等因素推动的。然而，缺乏核准治疗 PSC 的药物以及发病机制的复杂性可能会阻碍市场成长。持续研发新疗法和增加新兴市场的医疗保健支出可以为市场参与企业带来巨大的商机。
本研究的主要特点
该报告对全球原发性硬化性胆管炎市场进行了详细分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模和年复合成长率（CAGR%）。
它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
根据公司亮点、产品系列、主要亮点、绩效和策略等参数对全球原发性胆管炎市场的主要企业进行了分析。
本研究涵盖的主要企业包括 Intercept Pharmaceuticals、Dr. Falk Pharma GmbH 和 Acorda Therapeutics Inc。
该报告的见解使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
全球原发性硬化性胆管炎市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过用于分析全球原发性硬化性胆管炎市场的各种策略矩阵，将促进相关人员的决策。
目录
第一章 研究目的与前提
- 研究目的
- 先决条件
- 简称
第二章 市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map（COM）
第三章市场动态、法规及趋势分析
- 市场动态
- 促进因素
- 抑制因素
- 机会
- 影响分析
- 市场趋势
- 主要进展
- 监管场景
- 收购和合作场景
- 资金筹措和投资
- PEST分析
- 波特的分析
第四章全球原发性硬化性胆管炎市场－COVID-19 的影响
- 整体影响
- 政府倡议
- COVID-19 对市场的影响
第五章全球原发性硬化性胆管炎市场，依药物类别，2019-2031（百万美元）
- 熊去氧胆酸 (UDCA)
- 皮质类固醇
- Azathioprine
- Mercaptopurine
- Budesonide
- 奥贝胆酸
- 单株抗体
- 其他的
第六章 全球原发性硬化性胆管炎市场，依给药途径，2019-2031 年（百万美元）
- 口服
- 胃肠外的
- 其他的
第七章 全球原发性硬化性胆管炎市场，依分销管道划分，2019-2031 年（百万美元）
- 医院药房
- 零售药房
- 网路药房
第八章全球原发性硬化性胆管炎市场，按地区，2019-2031（百万美元）
- 拉丁美洲
- 欧洲
- 亚太地区
- 中东
第9章 竞争格局
- 公司简介
- Acorda Therapeutics, Inc.
- Gilead Sciences, Inc.
- NGM Biopharmaceuticals, Inc.
- Intercept Pharmaceuticals, Inc.
- Dr. Falk Pharma GmbH
- Allergan Plc.
- Shire Plc.
- Durect Corporation
- Conatus Pharmaceuticals, Inc.
- Sirnaomics, Inc.
- Shenzhen HighTide Biopharmaceutical Ltd.
- Cymabay Therapeutics
- Pliant Therapeutics
- Immunic AG
第10章分析师建议
- 命运之轮
- 分析师观点
- 一致的机会图
第十一章 参考文献与调查方法
- 参考
- 调查方法
Global primary sclerosing cholangitis market is estimated to be valued at USD 161.2 Mn in 2024 and is expected to reach USD 273.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.8% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 161.2 Mn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 7.80% | 2031 Value Projection: | US$ 273.1 Mn |
Primary sclerosing cholangitis (PSC) is a chronic progressive cholestatic liver disease characterized by multifocal strictures and fibrosis of the intrahepatic and extrahepatic bile ducts. It is associated with inflammatory bowel disease, usually ulcerative colitis, in 70-80% of cases. The exact cause of PSC remains unknown, but it is believed to be an autoimmune disease resulting from a complex interplay between genetic susceptibility and environmental triggers. The global prevalence of PSC is estimated to range between 13-16 cases per 100,000 individuals. Currently, there is no cure for PSC and treatment is focused on relieving symptoms and slowing disease progression. Global primary sclerosing cholangitis market growth is driven by increasing diagnosis rates and rising healthcare expenditure.
Market Dynamics:
Global primary sclerosing cholangitis market growthis driven by factors like rising awareness about the disease, increasing diagnosis rates attributed to advanced diagnostic modalities, and growing geriatric population worldwide who are more susceptible to develop PSC. However, lack of an approved drug for treating PSC and complexities associated with the disease pathogenesis can hamper the market growth. Ongoing R&D for developing novel therapeutics and increasing healthcare expenditures in emerging nations can present high-impact profitable opportunities for market players.
Key Features of the Study:
This report provides in-depth analysis of the global primary sclerosing cholangitis market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global primary sclerosing cholangitis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Intercept Pharmaceuticals, Dr. Falk Pharma GmbH, and Acorda Therapeutics Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global primary sclerosing cholangitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global primary sclerosing cholangitis market
Detailed Segmentation-
- By Drug Class
- Ursodeoxycholic acid (UDCA)
- Corticosteroids
- Azathioprine
- Mercaptopurine
- Budesonide
- Obeticholic acid
- Monoclonal antibody
- Others
- By Route of Administration
- Oral
- Parenteral
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Acorda Therapeutics, Inc.
- Gilead Sciences, Inc.
- NGM Biopharmaceuticals, Inc.
- Intercept Pharmaceuticals, Inc.
- Falk Pharma GmbH
- Allergan Plc.
- Shire Plc.
- Durect Corporation
- Conatus Pharmaceuticals, Inc.
- Sirnaomics, Inc.
- Shenzhen HighTide Biopharmaceutical Ltd.
- Cymabay Therapeutics
- Pliant Therapeutics
- Immunic AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global Primary Sclerosing Cholangitis Market- Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global Primary Sclerosing Cholangitis Market, By Drug Class, 2019 - 2031, (USD Mn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Ursodeoxycholic acid (UDCA)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Corticosteroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Azathioprine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Mercaptopurine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Budesonide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Obeticholic acid
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Monoclonal antibody
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
6. Global Primary Sclerosing Cholangitis Market, By Route of Administration, 2019 - 2031, (USD Mn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
7. Global Primary Sclerosing Cholangitis Market, By Distribution Channel, 2019 - 2031, (USD Mn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
8. Global Primary Sclerosing Cholangitis Market, By Region, 2019 - 2031, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Acorda Therapeutics, Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Gilead Sciences, Inc.
- NGM Biopharmaceuticals, Inc.
- Intercept Pharmaceuticals, Inc.
- Dr. Falk Pharma GmbH
- Allergan Plc.
- Shire Plc.
- Durect Corporation
- Conatus Pharmaceuticals, Inc.
- Sirnaomics, Inc.
- Shenzhen HighTide Biopharmaceutical Ltd.
- Cymabay Therapeutics
- Pliant Therapeutics
- Immunic AG
- Acorda Therapeutics, Inc.
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About Us and Sales Contact
